Özgür YAZICI, Kadriye AYDİN, Sule TEMİZKAN, Fehmi NARTER, Akif ERBİN, Alper KAFKASLI, Alkan ÇUBUK, Rahmi ASLAN, Kemal SARICA

Relationship Between Serum Asymmetrical Dimethylarginine Level and Urolithiasis

In the present prospective clinical human study, we focused on researching whether or not there is a difference between metabolic syndrome (MS) positive/negative and renal stone disease (SD) positive/negative patients with regard to asymmetrical dimethylarginine (ADMA) serum levels to clarify the possible effect of endothelial cell dysfunction on renal SD. We included 76 patients (17 males and 59 females) who were admitted to the endocrinology and urology outpatient clinic between December 2014 and February 2018. Patients were segregated into 4 groups; group 1; MS (–) SD (-), group 2; MS (–) SD (+), group 3; MS (+) SD (-) and group 4; MS (+) SD (+). Patients’ age, sex, medical history, and anthropometric measurements were recorded. Endothelial dysfunction was assessed with serum ADMA levels. The mean age was 40.1 ± 11.4 years (range: 18–59). There was a statistically significant difference between groups for mean homocysteine, uric acid and BMI values. However, there was no statistically sign ificant difference between groups for mean CRP, age and creatinine values. The mean ADMA value was 152 ± 77 (range: 51–445). There was no statistically significant difference between groups for the mean ADMA values. These results showed that studies must focus on MS components separately from each other and sex distribution between patients must be homogeneous or different sexes must be examined separately. In addition, stone compositions of patients enrolled in the study must be known to arrive at more trustworthy and worthwhile results

PDF

___

1. Ramello A, Vitale C and Marangella M: Epidemiology of nephrolithiasis. J Nephrol, suppl. 2000; 13: 45-50.

2. Muslumanoglu AY, Binbay M, Yuruk E, et al. Updated epidemiologic study of urolithiasis in Turkey. I: changing characteristics of urolithiasis. Urol Res 2011; 39: 309- 314.

3. Soucie JM, Coates RJ, McClellan W, Austin H, Thun M. Relation between geographic variability in kidney stones prevalence and risk factors for stones. Am J Epidemiol 1996; 143: 487-495.

4. Obligado SH, Goldfarb DS. The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 2008; 21: 257-264.

5. Lieske JC, de la Vega LS, Gettman MT, et al. Diabetes mellitus and the risk of urinary tract stones: a population-based case–control study. Am J Kidney Dis 2006; 48: 897-904.

6. Jeong IG, Kang T, Bang JK, et al. Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney 2011; 58: 383-388.

7. Verkoelen CF, van der Boom BG. Increased calcium oxalate monohydrate crystal binding to injured renal tubular epithelial cells in culture. Am J Physiol 1998; 274: 958-965.

8. Linas SL, Repine JE. Endothelial cells regulate proximal tubule epithelial cell sodium transport. Kidney Int 1999; 55: 1251-1258.

9. Aydin H, Yencilek F, Mutlu N, et al. Ethylene glycol induced hyperoxaluria increases plasma and renal tissue asymmetrical dimethylarginine in rats: a new pathogenetic link in hyperoxaluria induced disorders. J Urol 2010; 183: 759-764.

10. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.

11. D.R. Matthews, J.P. Hosker, A.S. Rudenski, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 1985; 28: 412-419.

12. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 444-2449.

13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA 2002; 287: 356-359.

14. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 2003; 63: 1817-1823.

15. Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and epidemiological characteristics of urolithiasis in Japan: trends between 1965 and 2005. Urology 2008; 71: 209-213.

16. West B, Luke A, Durazo-Arvizu RA, Cao G, Shoham D, Kramer H. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988–94. Am J Kidney 2008; 51: 741-747.

17. Jeong IG, Kang T, Bang JK, et al. Association between metabolic syndrome and the presence of kidney stones in a screened population. Am J Kidney 2011; 58: 383-388.

18. Ando R, Suzuki S, Nagaya T, et al. Impact of insülin resistance, insulin and adiponectin on kidney stones in theJapanese population. Int J Urol 2011; 18: 131-138.

19. Kim YJ, Kim CH, Sung EJ, Kim SR, Shin HC, Jung WJ. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism Journal 2013; 62: 808-813.

20. Cho ST, Jung SI, Myung SC, Kim TH. Correlation of metabolic syndrome with urinary stone composition. Int J Urol 2013; 20: 208-213.